Trial Profile
First Line Treatment of Elderly Patients With Advanced or Metastatic NSCLC With Docetaxel and Bevacizumab
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Sep 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 May 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 08 Jul 2014 New trial record